Flexible and scalable nonviral delivery for cGMP cell therapy processing

Closed manufacturing systems of cell therapies have a number of benefits, reducing human error, contamination risk and allowing multiple processes to be run at once in parallel. Non-viral gene delivery methods such as transfection can be optimized in closed manufacturing systems, utilizing CRISPR-Cas9 to enhance performance and safety over traditional methods of vector integration. 

In this application note, Thermo Fisher compares the CTS Xenon Electroporation System with the Invitrogen Neon Transfection System, a small-scale benchtop device suitable for research and early process development. The CTS Xenon System demonstrates its ability to deliver consistently high viability, transfection efficiency and minimal change in phenotype. With 12-38% knock-in efficiency, it can potentially be used to easily scale and optimize the transfection process in a closed system.  

Discover the speed, scalability, performance and flexibility of this system.  

This content was supplied by Thermo Fisher Scientific.

Thermo_SC_March2022-Neon-to-Xenon-AppNote-Global-FWR